AYA Leukemia Survivors Have Higher Mortality Rates Than the General Population
Although considered a rare occurrence in adolescents and young adults (AYAs), aged 15 to 39 years, the incidence...
PARP1-Selective Inhibitor Offers Significant Benefits Over Older Predecessors in Treatment of Solid Tumors
The first-in-human, first-in-class trial of the next-generation PARP (poly [ADP-ribose] polymerase) 1–selective inhibitor AZD5305...
Age at Initiation of Colorectal Cancer Screening and Risk of Colorectal Cancer Among U.S. Women
In a study reported in JAMA Oncology, Ma et al found that the initiation of lower gastrointestinal endoscopy screening in women...
AML Study Shows Benefit of CPX-351 vs Hypomethylating Agent Plus Venetoclax in Subgroup of Older Adults
For older patients with acute myeloid leukemia (AML), front-line treatment with liposomal daunorubicin/cytarabine (CPX-351)...
ASCO Coronavirus Resources
As the coronavirus (COVID-19) continues to spread, ASCO is committed to providing the most current information and resources to its members and the larger oncology...
Louis Staudt and Wyndham Wilson: Phase III Trials and Tribulations
Lisa Carey: Immune Checkpoint Inhibitors in Neoadjuvant or Adjuvant Therapy for TNBC
Rachel Grisham: MEK Inhibition Is Now a Standard of Care in Recurrent Low-Grade Serous Ovarian Cancer
James Smithy and Margaret Callahan: Relatlimab Plus Nivolumab Worthy of Further Study in Advanced Melanoma and Beyond
Neal Meropol: Reflections on the Evolution of Clinical Care Since the Passage of the National Cancer Act
Sponsored Content
Sponsored by Adaptive Biotechnologies
The Role of Minimal Residual Disease Assessment in Guiding Personalized Care in Multiple Myeloma
Sponsored by Pfizer Medical Affairs
Considerations in the Front-Line Treatment of Hormone Receptor–Positive/HER2-Negative Advanced Breast Cancer
PET Response–Adapted Chemoradiotherapy for Esophageal and Esophagogastric Junction Adenocarcinoma
As reported in the Journal of Clinical Oncology by Karyn A. Goodman, MD, and colleagues, mature results of the phase II CALGB 80803/Alliance trial indicated that treatment guided by early positron-emission tomography (PET) assessment of response to induction neoadjuvant chemotherapy improved...
Impact of Genes on Total Number and Type of Nevi
A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer. “The goal was to investigate the genetic underpinnings of different mole classes, or...
Sotorasib for KRAS G12C–Mutated NSCLC: Overall Survival and Exploratory Subgroup Analyses
Results from the phase II cohort of the CodeBreaK 100 study showed that treatment with the KRAS G12C inhibitor sotorasib achieved a 37.1% objective response rate and a median overall survival of 12.5 months in previously treated patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC)....
Organizations Issue Statement Encouraging Return to HPV Vaccination
Doctors and scientists across America at National Cancer Institute (NCI)-designated cancer centers and other organizations recently issued a joint statement urging the nation’s health-care systems, physicians, parents, children, and young adults to get human papillomavirus (HPV) vaccination back on ...
Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma
In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...
Electronic Olfaction System Under Study as Screening Tool for Pancreatic and Ovarian Cancers
An odor-based test that detects vapors emanating from blood samples was able to distinguish between benign and pancreatic and ovarian cancer cells with up to 95% accuracy, according to a new study presented by Johnson et al during the 2021 ASCO Annual Meeting (Abstract 5544). The findings suggest...
Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...
